Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.

Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N.

Leuk Res. 2014 Mar;38(3):361-70. doi: 10.1016/j.leukres.2013.11.017. Epub 2013 Dec 1.

PMID:
24367893
2.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Erratum in: Leukemia. 2017 May;31(5):1253-1254.

3.

Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.

Masuzawa A, Kiyotani C, Osumi T, Shioda Y, Iijima K, Tomita O, Nakabayashi K, Oboki K, Yasuda K, Sakamoto H, Ichikawa H, Hata K, Yoshida T, Matsumoto K, Kiyokawa N, Mori T.

Eur J Haematol. 2014 Mar;92(3):263-7. doi: 10.1111/ejh.12234. Epub 2013 Nov 28.

PMID:
24215620
4.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J.

Blood. 2005 Jun 15;105(12):4849-52. Epub 2005 Feb 15.

PMID:
15713800
5.

Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.

Yeh CH, Abdool A, Bruey JM.

Cancer Biomark. 2010;7(6):295-303. doi: 10.3233/CBM-2010-0193.

PMID:
21694468
6.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG.

J Hematol Oncol. 2011 Feb 7;4:6. doi: 10.1186/1756-8722-4-6.

7.

Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.

Moore FR, Yang F, Press RD.

Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.

PMID:
23666688
8.

Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.

Bellisola G, Cinque G, Vezzalini M, Moratti E, Silvestri G, Redaelli S, Gambacorti Passerini C, Wehbe K, Sorio C.

Analyst. 2013 Jul 21;138(14):3934-45. doi: 10.1039/c2an36393c.

PMID:
23323262
9.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78.

10.

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O.

Int J Oncol. 2013 Feb;42(2):419-28. doi: 10.3892/ijo.2012.1729. Epub 2012 Dec 6.

11.

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.

O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93.

12.

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.

Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.

13.
14.

Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.

Itonaga H, Tsushima H, Imanishi D, Hata T, Doi Y, Mori S, Sasaki D, Hasegawa H, Matsuo E, Nakashima J, Kato T, Horai M, Taguchi M, Matsuo M, Taniguchi H, Makiyama J, Sato S, Horio K, Ando K, Moriwaki Y, Sawayama Y, Ogawa D, Yamasaki R, Takasaki Y, Imaizumi Y, Taguchi J, Kawaguchi Y, Yoshida S, Joh T, Moriuchi Y, Nonaka H, Soda H, Fukushima T, Nagai K, Kamihira S, Tomonaga M, Yanagihara K, Miyazaki Y.

Leuk Res. 2014 Jan;38(1):76-83. doi: 10.1016/j.leukres.2013.10.022. Epub 2013 Nov 5.

PMID:
24262285
16.

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.

Am J Hematol. 2013 May;88(5):385-93. doi: 10.1002/ajh.23419. Epub 2013 Mar 27.

17.

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.

Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C.

Br J Haematol. 2012 May;157(4):446-56. doi: 10.1111/j.1365-2141.2012.09078.x. Epub 2012 Feb 29.

PMID:
22372463
18.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11.

PMID:
18268096
19.

Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.

De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O.

Leukemia. 2008 Dec;22(12):2208-16. doi: 10.1038/leu.2008.242. Epub 2008 Sep 11.

PMID:
18784740
20.

Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.

Byrgazov K, Lucini CB, Berkowitsch B, Koenig M, Haas OA, Hoermann G, Valent P, Lion T.

Oncotarget. 2016 Nov 22;7(47):78083-78094. doi: 10.18632/oncotarget.12943.

Supplemental Content

Support Center